Literature DB >> 27989322

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Timothy H J Goodship1, H Terence Cook2, Fadi Fakhouri3, Fernando C Fervenza4, Véronique Frémeaux-Bacchi5, David Kavanagh6, Carla M Nester7, Marina Noris8, Matthew C Pickering2, Santiago Rodríguez de Córdoba9, Lubka T Roumenina10, Sanjeev Sethi11, Richard J H Smith12.   

Abstract

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C3 glomerulopathy; anti-complement therapies; atypical hemolytic uremic syndrome; complement; glomerulonephritis; kidney disease

Mesh:

Substances:

Year:  2016        PMID: 27989322     DOI: 10.1016/j.kint.2016.10.005

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  154 in total

1.  C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.

Authors:  Sjoerd A M E G Timmermans; Myrurgia A Abdul-Hamid; Judith Potjewijd; Ruud O M F I H Theunissen; Jan G M C Damoiseaux; Chris P Reutelingsperger; Pieter van Paassen
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

Review 2.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

3.  Mother and Child Reunion in "Hypertensive" End-Stage Renal Disease: Will They Complement Each Other?

Authors:  Sjoerd A M E G Timmermans; Pieter van Paassen
Journal:  Nephron       Date:  2019-03-14       Impact factor: 2.847

4.  Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion.

Authors:  Andrew Jay Portuguese; Brea Lipe
Journal:  Blood Adv       Date:  2018-12-11

5.  Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Authors:  Mariana Ciocchini; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2018-05-28       Impact factor: 2.370

6.  Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.

Authors:  Gema Ariceta
Journal:  Pediatr Nephrol       Date:  2019-01-28       Impact factor: 3.714

7.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

Review 8.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

9.  Controversies of the classification of TMA and the terminology of aHUS.

Authors:  Hideki Kato; Masaomi Nangaku; Hirokazu Okada; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2017-12-27       Impact factor: 2.801

Review 10.  [The complement system-a "hot topic" not only for kidney diseases].

Authors:  Kerstin Amann; Christoph Daniel; Maike Büttner-Herold
Journal:  Pathologe       Date:  2020-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.